Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
FOXO Technologies ( (FOXO) ) has provided an announcement.
On March 27, 2026, FOXO Technologies’ majority stockholder, Rennova Health, approved by written consent an amendment to FOXO’s Certificate of Incorporation to increase authorized Class A common shares from 10 billion to 25 billion, with the effective date left to the discretion of FOXO’s board. FOXO filed a preliminary Schedule 14C information statement with the U.S. Securities and Exchange Commission on April 1, 2026, and the share increase will become effective 20 days after mailing of the definitive statement to stockholders of record as of March 20, 2026, signaling a major expansion of the company’s capacity to issue equity.
The move consolidates the CEO-controlled majority stockholder’s influence over FOXO’s capital structure, as no further stockholder approval will be required before the amendment is filed. This substantial increase in authorized shares could have significant implications for future financings, potential dilution, and the company’s strategic flexibility in pursuing corporate transactions or restructuring options.
The most recent analyst rating on (FOXO) stock is a Hold with a $0.01 price target. To see the full list of analyst forecasts on FOXO Technologies stock, see the FOXO Stock Forecast page.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Neutral.
The score is primarily held back by persistent losses and continued operating/free-cash-flow burn despite improving revenue and gross margin trends. Corporate events add mixed impact (operational progress but higher dilution risk), while valuation remains constrained by negative earnings and technicals cannot be substantiated from the missing indicator set.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. is a Delaware corporation whose majority voting control is held by Rennova Health, Inc., which is controlled by FOXO’s CEO. As of March 20, 2026, Rennova Health held approximately 97.59% of FOXO’s voting rights directly or by proxy, effectively determining key corporate and capital structure decisions on its own.
Technical Sentiment Signal: Sell
Current Market Cap: $3,063
See more insights into FOXO stock on TipRanks’ Stock Analysis page.